Aims We conducted a systematic review and meta-analysis on three outcomes. We
assessed the efficacy and safety of direct oral anticoagulants (DOAC) compared to vitamin K …

Abstract Background Direct oral anticoagulants (DOACs) have become favorable choices for
anticoagulation due to their fixed-dose schedule, limited need for monitoring, and non …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Background Anticoagulation is an effective treatment in prevention of stroke in patients with
atrial fibrillation (AF). Direct anticoagulants (DOACs) have been favored over vitamin K …

Background Recent guidelines caution against the use of non-vitamin K antagonists oral
anticoagulants (NOACs) in patients with extremely high body weight (≥ 120 kg) due to lack …

Background Data on the relationship between body mass index (BMI), thromboembolic
events (TEE) and bleeding in patients with atrial fibrillation (AF) are controversial, and further …

Objectives: Clinical data for the safety and efficacy of Factor Xa (FXa) inhibitors in severely
obese patients is limited. Additional information is needed to assess the risks and benefits of …

To investigate the effect of low-dose rivaroxaban on bleeding events in low-weight patients
with nonvalvular atrial fibrillation. A retrospective study was conducted in patients with …

Patients at extremes of body weight are underrepresented in randomized controlled trials of
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …